FDA Expands Approval of Pembrolizumab for First-Line Treatment of Non-Small Cell Lung Cancer

FDA approved the immune checkpoint inhibitor pembrolizumab to be used with chemotherapy as a first-line treatment for non-small cell lung cancer.

Cancer Currents: An NCI Cancer Research Blog